Function of branched-chain amino acid catabolism in lung cancer cells

doi:10.3969/j.issn.1674-8115.2021.07.003

Abstract

Abstract: Objective

·To explore the function and mechanism of branched-chain amino acid (BCAA) catabolism in lung cancer cells.

Methods

·Small interfering negative control (siNC) and small interfering branched-chain keto acid dehydrogenase kinase (siBCKDK) were transfected into non-small cell lung cancer cells H1299, A549 and HCC827 by instantaneous transfection. The expression of BCKDK, branched-chain keto acid dehydrogenase e1, α polypeptide (BCKDE1α) and its phosphorylation in siNC group and siBCKDK group were detected by Western blotting. The proliferation activity of the above two groups of cells was detected by CCK-8 assay. The above three kinds of cells were cultured in culture medium containing 0, 100, 200 μmol/L BT2 (3, 6-dichlorobenzo[b]thiophene-2-carboxylic acid), respectively. The expression of BCKDE1α and its phosphorylation were detected by Western blotting. The proliferation activity of 0 μmol/L BT2 group and 200 μmol/L BT2 group was detected by CCK-8 assay. The cell viability of siNC group and siBCKDK group, 0 μmol/L BT2 group and 200 μmol/L BT2 group in H1299 and A549 cells was calculated by trypan blue staining. Cell number at different phases of cell cycle was detected by propidium iodide staining. Cyclin-dependent kinase inhibitor 1A (P21) expression was detected by Western blotting.

Results

·In H1299, A549 and HCC827 cells, compared with siNC group, expression of BCKDK and phosphorylation of BCKDE1α in siBCKDK group were down-regulated, and the proliferation activity was decreased (all P=0.000). Compared with 0 μmol/L BT2 group, the phosphorylation of BCKDE1α was down-regulated in H1299, A549 and HCC827 cells in both 100 μmol/L BT2 group and 200 μmol/L BT2 group, but more obviously in 200 μmol/L BT2 group. The cell proliferation activity in 200 μmol/L BT2 group was decreased compared with that in 0 μmol/L BT2 group (all P=0.000). There was no significant difference in the cell viability of H1299 and A549 cells between siBCKDK group and siNC group, 200 μmol/L BT2 group and 0 μmol/L BT2 group, but G0/G1 cell cycle arrest occurred (all P<0.05) with the expression of P21 increasing.

Conclusion

·siBCKDK and BT2 can promote the dephosphorylation of BCKDE1α and accelerate the catabolism of BCAA, which may inhibit the proliferation of lung cancer cells by up-regulating P21 and blocking cell cycle.

Key words: branched-chain amino acids (BCAA), lung cancer, cell proliferation

CLC Number:

R363.2⁺1

Yan-qi HE, Rui CHI, Meng-ping CHEN, Si CHEN, Chun-liang LIU, Yun-xia LIU, Hai-peng SUN. Function of branched-chain amino acid catabolism in lung cancer cells[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(7): 858-864.

Figures/Tables 7

Fig 1 Effect of siBCKDK on BCKDK protein expression and BCKDE1α phosphorylation in NSCLC cells

Fig 2 Effect of siBCKDK on proliferation of NSCLC cells

Fig 3 Effect of BT2 on phosphorylation of BCKDE1α in NSCLC cells

Fig 4 Effect of BT2 on proliferation of NSCLC cells

Fig 5 Effects of siBCKDK or BT2 on the survival rate of NSCLC cells

Fig 6 Effect of siBCKDK or BT2 on cell cycle of NSCLC cells

Fig 7 Effects of siBCKDK or BT2 on expression of P21 in NSCLC cells

TrendMD

References 20

1	World Health Organization. Cancer today[DB/OL]. [2020-11-23]. .
2	Osmani L, Askin F, Gabrielson E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy[J]. Semin Cancer Biol, 2018, 52(Pt 1): 103-109.
3	Tso SC, Gui WJ, Wu CY, et al. Benzothiophene carboxylate derivatives as novel allosteric inhibitors of branched-chain α-ketoacid dehydrogenase kinase[J]. J Biol Chem, 2014, 289(30): 20583-20593.
4	Sun H, Olson KC, Gao C, et al. Catabolic defect of branched-chain amino acids promotes heart failure[J]. Circulation, 2016, 133(21): 2038-2049.
5	Zhou M, Shao J, Wu CY, et al. Targeting BCAA catabolism to treat obesity-associated insulin resistance[J]. Diabetes, 2019, 68(9): 1730-1746.
6	Fu T, Liang AL, Liu YJ. Role of P21 in resistance of lung cancer[J]. Chin J Lung Cancer, 2020, 23(7): 597-602.
7	Al-Sharaky DR, Kandil MAE, Aiad HAS, et al. ROC-1, P21 and CAIX as markers of tumor aggressiveness in bladder carcinoma in Egyptian patients[J]. Diagn Pathol, 2020, 15(1): 33.
8	Mayers JR, Wu C, Clish CB, et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development[J]. Nat Med, 2014, 20(10): 1193-1198.
9	Ericksen RE, Lim SL, McDonnell E, et al. Loss of BCAA catabolism during carcinogenesis enhances mTORC1 activity and promotes tumor development and progression[J]. Cell Metab, 2019, 29(5): 1151-1165. e6.
10	Li JT, Yin M, Wang D, et al. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma[J]. Nat Cell Biol, 2020, 22(2): 167-174.
11	Reina-Campos M, Moscat J, Diaz-Meco M. Metabolism shapes the tumor microenvironment[J]. Curr Opin Cell Biol, 2017, 48: 47-53.
12	Budhathoki S, Iwasaki M, Yamaji T, et al. Association of plasma concentrations of branched-chain amino acids with risk of colorectal adenoma in a large Japanese population[J]. Ann Oncol, 2017, 28(4): 818-823.
13	Nezami Ranjbar MR, Luo Y, di Poto C, et al. GC-MS based plasma metabolomics for identification of candidate biomarkers for hepatocellular carcinoma in Egyptian cohort[J]. PLoS One, 2015, 10(6): e0127299.
14	Tönjes M, Barbus S, Park YJ, et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1[J]. Nat Med, 2013, 19(7): 901-908.
15	Hattori A, Tsunoda M, Konuma T, et al. Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia[J]. Nature, 2017, 545(7655): 500-504.
16	Zhang L, Han JQ. Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function[J]. Biochem Biophys Res Commun, 2017, 486(2): 224-231.
17	Chen M, Zhang H, Zhang G, et al. Targeting TPX2 suppresses proliferation and promotes apoptosis via repression of the PI3k/AKT/P21 signaling pathway and activation of p53 pathway in breast cancer[J]. Biochem Biophys Res Commun, 2018, 507(1/2/3/4): 74-82.
18	Zhou L, Sheng WW, Jia C, et al. Musashi2 promotes the progression of pancreatic cancer through a novel ISYNA1-p21/ZEB-1 pathway[J]. J Cell Mol Med, 2020, 24(18): 10560-10572.
19	Zhou XY, Liu H, Ding ZB, et al. lncRNA SNHG16 exerts oncogenic functions in promoting proliferation of glioma through suppressing p21[J]. Pathol Oncol Res, 2020, 26(2): 1021-1028.
20	Liu X, Zhang F, Zhang Y, et al. PPM1K regulates hematopoiesis and leukemogenesis through CDC20-mediated ubiquitination of MEIS1 and p21[J]. Cell Rep, 2018, 23(5): 1461-1475.

[1]	Yun-fang MA, Li-na PAN, Zhen LI, Bei-li GAO, Jia-an HU, Zhi-hong XU. Exploratory study on downregulation of PD-L1 in KRAS G12V-mutant non-small cell lung cancer cells by selumetinib [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(6): 741-748.
[2]	Jian-hua XU, Ping JIANG, Jiong DENG. Expression and significance of ATP-binding cassette superfamily G member 2 in lung cancer [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(6): 830-833.
[3]	XU Shu-lin, WU Jing, LOU Jia-tao. Correlation analysis of lung cancer and anemia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(11): 1500-1504.
[4]	HE Chun-ming, YIN Hang, TANG Jian, DING Yi-zong, FU Yu-jie, ZHAO Xiao-jing. Establishment and internal validation of a prognostic model for elderly patients after lung cancer surgery based on SEER [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(11): 1554-1561.
[5]	ZHOU Zhen, XU Yun-hua, ZHANG Fei-fei, ZHAO Yi, GUO Lin, FU Guo-long, SHEN Sheng-ping, LENG Xue-jiao. Establishment of a lung cancer momodel with humanized immunity and its role in efficacy evaluation of programmed death-1 inhibitors [J]. , 2020, 40(1): 37-.
[6]	YAN Yu-qing, SHEN Chao-qin, CHEN Hao-yan, HONG Jie#, WANG Zhen-hua#. Expression of lnc-MTBP-5 in colorectal cancer and its effect on cell invasion [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(09): 1193-1201.
[7]	ZOU Chen1, 2, XU Run-hao1, 3, ZHANG Hong2, MA Zhan2, CHEN Li2, ZHANG Jie3, LI Min3, ZHANG Shu-lin1. Potential roles of small metabolites in the differential diagnosis between lung cancer and pneumonia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(08): 1041-1047.
[8]	HE Chun-ming, YIN Hang, ZHENG Jia-jie, TANG Jian, FU Yu-jie, ZHAO Xiao-jing. Immunotherapy for lung cancer: immunosuppressive cells and intrapulmonary immunity [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(08): 1137-1142.
[9]	QU Guo-jun1, LU Yuan-feng2, LI Yu1. Mechanism of CCT2, a new downstream substrate of PDGFRα, on proliferation of tumor cells [J]. , 2019, 39(1): 28-.
[10]	SUN Bao-hangxing1, LU Yi1, WANG Yi-qing1, ZHOU Jia-le1, LIN Meng-lu1, SONG Wei2, JIANG Meng1, BU Jun1. Comparative cultivation of single cell derived placental mesenchymal stromal cells in vitro [J]. , 2018, 38(9): 1033-.
[11]	HE Ya-ping1, LOU Wei-qun2, CHEN Jie-ling2, ZHOU Zhen3, ZHU Jing-fen1, JIAN Hong3. Influencing factors for quality of life in patients over 12 months after diagnosis of non-small cell lung cancer [J]. , 2018, 38(7): 775-.
[12]	XU Hua-li, LIU Wen-xue, SHEN Fang-qian, XI Xiao-wei. Effects of UBE3C on proliferation and invasion in ovarian cancer SKOV3 cells [J]. , 2018, 38(6): 610-.
[13]	DAI Wei, WANG Xiao-wen, HUANG Chun, XIANG Xiao-yong, JIANG Yin-jiu, WU Qing-chen. Research progress in the risk factors and mechanisms of postoperative atrial fibrillation after lung cancer surgery [J]. , 2018, 38(5): 573-.
[14]	ZHANG Li-yan, TAN Xiao-ming. Application in diagnosis and treatment of circulating tumor cell detection in lung cancer#br# [J]. , 2018, 38(3): 343-.
[15]	YU Huan1,LI Qing-yun2. Research progress of the local treatments on choroidal metastasis of lung cancer [J]. , 2018, 38(2): 233-.